Previous studies have found that high-concentration PGD2, reaching to 3.5 μg/mL, could inhibit the development of various tumors, including gastric cancer [10], prostate tumor [14], astrocytoma [26] and colon cancer [27]. Here, HPGDS is linked to astrocytoma (excluding glioblastoma).